iNexin™ Ophthalmic Solution
Preclinical
Phase 1
Phase 2
Phase 3
Ophthalmology
Corneal
Injury
iNexin™
Retinal
Diseases
iNexin™ Ophthalmic Solution
Investigating indications with significant unmet medical needs
Corneal Injury
The bulk of eye trauma related emergency visits are due to corneal injury. These can be trauma or exposure induced, and the resulting injuries span from discomfort to vision-threatening.
Retinal Diseases
Retinal Diseases impact the back of the eye, and often result in visual symptoms. While some causes do have treatments, many do not, and there is a lot of room to improve patient outcomes.
iNexin™ Ophthalmic Solution for the treatment of corneal injury has the potential to improve patient outcomes by regulating inflammatory response to promote improved ocular healing.
In initial studies, iNexin™ demonstrated:
Acceleration of corneal re-epithelialization
Reduction of corneal edema and inflammation
Restoration of the ocular surface
Safe and tolerable delivery
Revolutionizing the Way the Body Responds to Injury
Xequel’s aCT1 technology platform is designed to stimulate healing by creating an improved injury response. Our proprietary aCT1 technology restores the gap junctions to normalize cell-to-cell signaling and facilitate proper healing.
